Papers/PMID:36326979
Zinc supplement use and risk of aggressive prostate cancer: a 30-year follow-up study.
European journal of epidemiology2022The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
Zn(2+) — no detected effect on prostate cancer incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“We did not find statistically significant associations for zinc supplement and risk of overall, localized, low- or intermediate-grade prostate cancer.”
Quoted verbatim from Zinc supplement use and risk of aggressive prostate cancer: a 30-year follow-up study.. - Study
- cohort
- Dose
- self-reported supplemental zinc use, categories 1-24, 25-74 and >=75 mg/day, and duration up to >=15 years
- Population
- Men in the Health Professionals Follow-up Study (47,240 men without prior cancer), supplemental zinc use compared with never-users, median follow-up 28.3 years; overall prostate cancer, localized and low- or intermediate-grade subtypes
Zinc supplement use and risk of aggressive prostate cancer: a 30-year follow-up study.2022PMID:36326979Permalink